HSCA Comments to the Senate HELP Committee on Planning for the Next Pandemic
Dear Chairman Alexander and Ranking Member Murray:
On behalf of the Healthcare Supply Chain Association (HSCA), we applaud your leadership to promote U.S. public health preparedness and response. Through commitment to advancing recommendations to help prepare for the next pandemic, we can best work to provide critical support in emergencies facing this nation. The unprecedented nature of...
Learn MoreComments of the Healthcare Supply Chain Association on USTR Request for Comments on Additional Tariff Exclusions for COVID-19 Response
Dear Ambassador Lighthizer:
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Trade Representative (USTR) on additional modifications of actions regarding Chinese exports under Section 301. HSCA is dedicated to supporting patient care and ensuring healthcare providers have access to critical medical supplies needed to...
Learn MoreComments of the Healthcare Supply Chain Association (HSCA) on FDA Request for Comments on Ensuring a Competitive Marketplace for Biosimilars
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the U.S. Food and Drug Administration’s (FDA) request for comments and holding of workshop on a competitive marketplace for biosimilars. HSCA is committed to increasing competition and promoting innovation in the healthcare system, and we applaud FDA for collaborating with the U.S. Federal Trade Commission (FTC) to...
Learn MoreHSCA Releases Third Annual Report on Value GPOs Deliver to the Healthcare Supply Chain
Washington, DC (March 24, 2020) – The Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), today released its third annual report on the value that GPOs deliver to the healthcare system. The report, which was based on existing academic research and on a survey of HSCA member GPOs, found that GPOs deliver up to $34.1...
Learn MoreHSCA Applauds House Committee on Energy and Commerce for Commitment to Supporting Quality and Protecting Patients from Counterfeit Medical Products
Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with the House Committee on Energy and Commerce’s open mark-up session on the Safeguarding Therapeutics Act and twelve other bills:
“HSCA and its member group purchasing organizations (GPOs) applaud Representatives Engel, Guthrie,...
Learn MoreHSCA Statement on House Committee on Homeland Security Hearing on the Coronavirus
Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with “Confronting the Coronavirus: The Federal Response,” a hearing before the U.S. House Committee on Homeland Security:
“HSCA and its member healthcare group purchasing organizations (GPOs) applaud members of the House Committee...
Learn MoreComments of the Healthcare Supply Chain Association (HSCA) on FDA Request for Comments on the Importation of Prescription Drugs
Dear Commissioner Hahn:
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments to the U.S. Food and Drug Administration (FDA) regarding the importation of prescription drugs from Canada. HSCA is dedicated to ensuring patient access to affordable healthcare, and we applaud FDA for taking steps to reduce prescription drug costs, support...
Learn MoreHSCA Statement on Senate HELP Committee Hearing on the Coronavirus
Washington, DC (March 3, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with “An Emerging Disease Threat: How the U.S. Is Responding to COVID-19, the Novel Coronavirus,” a hearing before the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP):
“HSCA and its member healthcare group...
Learn MoreJoint Letter of Support for Swift Action on the MEDS Act
Dear Chairman Alexander and Ranking Member Murray,
As the United States takes steps in response to the outbreak of COVID-19, concerns with the integrity of the drug supply chain and the potential impact on downstream drug shortages have surfaced. While no drug shortages have been reported thus far in direct correlation with COVID-19, past situations such as H1N1, Ebola, and Hurricane Maria...
Learn MoreGroup Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
Dear Commissioner Hahn,
The undersigned groups share the Food and Drug Administration’s (FDA) deep commitment to the development of a robust biosimilars market and appreciate the Agency’s work to develop an efficient approval pathway for biosimilars to bring savings and access to America’s patients. As such, we support the approach outlined in the “Clinical Immunogenicity Considerations from...
Learn More